Soleno Therapeutics (NASDAQ:SLNO) Share Price Passes Above 50 Day Moving Average of $1.59

Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Rating) passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.59 and traded as high as $2.39. Soleno Therapeutics shares last traded at $2.37, with a volume of 37,826 shares.

Analysts Set New Price Targets

Separately, Oppenheimer lifted their price target on Soleno Therapeutics to $8.00 in a research note on Thursday, November 17th.

Soleno Therapeutics Trading Down 1.2 %

The company has a 50 day simple moving average of $1.59 and a 200 day simple moving average of $2.04. The stock has a market cap of $19.34 million, a P/E ratio of -0.72 and a beta of -0.03.

Soleno Therapeutics (NASDAQ:SLNO – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.29. As a group, sell-side analysts expect that Soleno Therapeutics, Inc. will post -0.48 earnings per share for the current year.

Hedge Funds Weigh In On Soleno Therapeutics

Several hedge funds have recently modified their holdings of the stock. Clayton Partners LLC bought a new stake in Soleno Therapeutics during the third quarter worth about $167,000. Renaissance Technologies LLC raised its stake in shares of Soleno Therapeutics by 309.6% during the 1st quarter. Renaissance Technologies LLC now owns 248,200 shares of the company’s stock worth $55,000 after purchasing an additional 187,600 shares in the last quarter. Finally, Worth Venture Partners LLC acquired a new stake in shares of Soleno Therapeutics in the 1st quarter valued at approximately $377,000.

About Soleno Therapeutics

(Get Rating)

Soleno Therapeutics, Inc engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The firm focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS).